Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
about
Nail PsoriasisNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastEvaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis.Immunophenotype lymphocyte of peripheral blood in patients with psoriasis.Associations of psoriatic arthritis and cardiovascular conditions in a large population.Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.Psoriasis and increased prevalence of hypertension and diabetes mellitus.Heel pain due to psoriatic arthritis in a 50 year old recreational male athlete: case report.Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective studyEffect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.Inverse psoriasis involving genital skin folds: successful therapy with dapsonePrevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control StudyIncidence, clinical manifestations and clipping of nail psoriasis in the dermatology center of the Hospital Universitário Evangélico de CuritibaEconomic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.New insights into the pathogenesis and genetics of psoriatic arthritis.Inflammatory arthritis: an overview for primary care physicians.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic diseaseChronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Natural Compounds for the Treatment of Psoriatic Arthritis: A Proposal Based on Multi-Targeted Osteoclastic Regulation and on a Preclinical StudyCritical role of environmental factors in the pathogenesis of psoriasis.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease.Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells.Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study.Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs.Psoriasis and lasting implications.Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study).Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.
P2860
Q22305813-7D850706-3B3A-4F51-B08F-DEB2CE064EC7Q22305855-2468C101-9029-4F49-ACB4-1C943C592BDAQ33673930-D22FD89A-49AE-409E-A50E-8C316AD1ADE9Q34557120-D14CC95D-A6C1-4FEE-8C6F-8F8EE14E3440Q34566497-CAE82894-087C-4881-B847-4E9BA986C067Q35232352-361BA64A-B364-481C-8AB1-D6F3091E6457Q35564637-B26EC977-E76D-40BC-A0EE-61FE910A135FQ35569003-E9499FCC-9DE2-4E2A-9AA9-B0592C542CFAQ35977689-7DC95BAA-D40F-467F-8EF1-E4041FA7280CQ36182389-F25F5311-A7FA-4186-AB47-AE9529C2F267Q36434768-2B4CBB08-EC7E-4AEE-ACE4-A001795768A4Q36708804-714CA449-E048-410D-9B13-5036FF3429EFQ37078889-B3B3EC49-F526-489F-93A3-6E739B25C545Q37268868-AB50258B-F99A-473F-A23A-47B2F2055CB7Q37381676-EA18E643-1CDB-477C-8AA0-8A4CAA191A05Q37427257-5FC2F9D0-9EAA-4E20-B204-9F46A9487A01Q37505449-A75A093C-0FFF-4211-9072-2D3C119369A3Q38201788-BCB6FDE3-AC56-47CB-92B7-B2BEF5FF7444Q38658975-ECD27C1A-431A-4483-B414-3385E1050572Q38871762-B5DE12B2-B2BA-4B6D-9149-B739B0165425Q38969036-24DA66CC-FD0D-412B-B01D-534623D6328CQ39117416-8D789D37-3393-474E-AED0-B68B12826CFDQ40738483-2ACC05E8-29B9-456D-985A-38B8E7E4CEC4Q41230071-CD1B86C8-97E8-4346-97B5-15E365A91C21Q41975429-7F98FD8A-A089-4E60-9FCA-4C8E26BFC0A8Q46138558-8FE865F1-6A78-4780-9641-75EB7D769F74Q48072913-1ADD6C92-6A0B-49CE-AB1A-1C16D9402F3AQ48239956-7F549139-A61B-48E6-8973-09E470CF261CQ48332071-9D4DE9A9-17F2-4D5D-98CD-CC1AEE7A3106Q51043569-A6ABB47A-24CC-4F8A-B01E-6D31216ABFC7
P2860
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@ast
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@en
type
label
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@ast
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@en
prefLabel
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@ast
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@en
P2093
P1476
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms.
@en
P2093
Alice B Gottlieb
Philip Mease
Wendy A Myers
P304
P356
10.1016/J.CLINDERMATOL.2006.07.006
P577
2006-09-01T00:00:00Z